New gel could shrink neurofibroma tumors without surgery
NCT ID NCT05005845
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a gel called NFX-179 on skin tumors in 199 adults with neurofibromatosis type 1. Participants applied the gel daily for 26 weeks. The study measured safety and whether tumors shrank in size or height. Results suggest the gel may help reduce tumor volume, but more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NFX-179 gel
What this could lead to
If successful, this gel could offer a non-surgical way to shrink or control skin tumors in people with neurofibromatosis type 1.
What could go wrong
This is a phase 2 trial with a small number of participants. The gel may not work for everyone, and long-term effects are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Apex Clinical Research Center, LLC
Mayfield Heights, Ohio, 44124, United States
-
Center for Dermatology Clinical Research, Inc.
Fremont, California, 94538, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana, 46250, United States
-
Derm Dox Center for Dermatology
Sugarloaf, Pennsylvania, 18249, United States
-
Dermatology Treatment and Research Center
Dallas, Texas, 75230, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Minnesota Clinical Study Center
New Brighton, Minnesota, 55112, United States
-
Northshore University HealthSystem
Evanston, Illinois, 60077, United States
-
Northwest Arkansas Clinical Trials Center, PLLC
Rogers, Arkansas, 72758, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Sadick Research Group, LLC
New York, New York, 10075, United States
-
Skin Search of Rochester, Inc.
Rochester, New York, 14623, United States
-
Skin Specialists, P.C.
Omaha, Nebraska, 68144, United States
-
The Education & Research Foundation, Inc.
Lynchburg, Virginia, 24501, United States
-
The Johns Hopkins School of Medicine
Baltimore, Maryland, 21287, United States
-
UTHealth McGovern Medical School
Houston, Texas, 77030, United States
-
University Clinical Trials, Inc.
San Diego, California, 92123, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205-7199, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27157, United States